<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616807</url>
  </required_header>
  <id_info>
    <org_study_id>LUP/MEX/2018/001</org_study_id>
    <nct_id>NCT04616807</nct_id>
  </id_info>
  <brief_title>An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders</brief_title>
  <official_title>An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients With Non-dystrophic Myotonic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lupin Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lupin Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional, prospective, observational, multicentre study to evaluate the&#xD;
      long-term safety and effectiveness of Namuscla in adult patients with NDM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, prospective, observational, multicentre study to evaluate the&#xD;
      long-term safety and effectiveness of Namuscla in adult patients with NDM. Namuscla should be&#xD;
      prescribed as per the approved Summary of Product Characteristics (SmPC).&#xD;
&#xD;
      Adult patients with non-dystrophic myotonic disorders who have been prescribed Namuscla by&#xD;
      the treating physician, and who meet the eligibility criteria will be enrolled in this study.&#xD;
&#xD;
      This includes:&#xD;
&#xD;
        -  Patients newly initiated on Namuscla for the treatment of NDM (newly exposed)&#xD;
&#xD;
        -  Patients already on Namuscla/ mexiletine at enrolment - For patients receiving&#xD;
           mexiletine other than Namuscla, only those who switch to Namuscla will be included in&#xD;
           the study.&#xD;
&#xD;
      Patients already being treated with Namuscla/ mexiletine at the time of enrolment will be&#xD;
      considered for enrolment provided they meet the eligibility criteria.&#xD;
&#xD;
      The study will be initiated at specialized centres for the treatment of myotonic disorders&#xD;
      (&quot;reference centres&quot;) in the United Kingdom (UK), France, and Germany, depending on&#xD;
      availability of Namuscla in the specific country. Depending on the enrolment and marketing&#xD;
      status (availability) of Namuscla in other countries in the EU, inclusion of additional sites&#xD;
      in other countries will be considered.&#xD;
&#xD;
      The study population will comprise patients who are diagnosed with non-dystrophic myotonic&#xD;
      disorders and considered suitable candidates for the treatment by Namuscla by the&#xD;
      investigators according to the approved SmPC. Patients will be enrolled over an approximate&#xD;
      2-year enrolment period and will be followed-up on-treatment for up to 3 years. Each enrolled&#xD;
      patient will be observed for 3 years or until discontinuation (if discontinued early).&#xD;
&#xD;
      For all enrolled patients, the baseline would be the latest data available at the enrolment&#xD;
      visit.&#xD;
&#xD;
      For the patients already on Namuscla, cumulative data (data related previous exposure as well&#xD;
      as current data) will be collected for adverse events (AEs) on Namuscla treatment.&#xD;
&#xD;
      No drug will be supplied for this study; patients will receive medicines through local&#xD;
      standard practices. All evaluations and investigations during the study will be performed&#xD;
      according to the routine clinical practices and discretion of the treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">February 24, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome 1 Proportion of patients with treatment-emergent AEs</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Proportion of patients with treatment-emergent AEs ([TEAEs], including SAEs) from study enrolment to 6, 12, 24 and 36 months on Namuscla</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Outcome 2 Proportion of patients requiring dose reduction or treatment discontinuation</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Proportion of patients requiring dose reduction or treatment discontinuation due to AEs (including SAEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Proportion of patients with AEs /SAEs/ Adverse Event of Special Interest (AESI)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Proportion of patients with AEs /SAEs/ Adverse Event of Special Interest (AESI) from study enrolment to 6, 12, 24, and 36 months</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myotonic Dystrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mexiletine</intervention_name>
    <description>Observational Study</description>
    <other_name>Namuscla ™</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will target the enrolment of 50 patients who are treated with Namuscla.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult, male or female patients with non-dystrophic myotonic disorders planned to be&#xD;
             started on Namuscla according to the approved SmPC&#xD;
&#xD;
          2. Patients already receiving Namuscla/mexiletine for the treatment of NDM; (for patients&#xD;
             on mexiletine other than Namuscla, only those who switch to Namuscla will be&#xD;
             enrolled).&#xD;
&#xD;
          3. Patients who understand and are willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are enrolled or participating in any other clinical trial for an&#xD;
             investigational product. -&#xD;
&#xD;
          2. Hypersensitivity to mexiletine, or to any of the excipients of Namuscla, or&#xD;
             hypersensitivity to any local anaesthetic&#xD;
&#xD;
          3. Ventricular tachyarrhythmia&#xD;
&#xD;
          4. Atrial tachyarrhythmia, fibrillation or flutter&#xD;
&#xD;
          5. Complete heart block (ie, third-degree atrioventricular block) or any heart block&#xD;
             susceptible to evolve to complete heart block (first-degree atrioventricular block&#xD;
             with markedly prolonged PR interval (≥ 240 ms) and/or wide QRS complex (≥ 120 ms),&#xD;
             second-degree atrioventricular block, bundle branch block, bifascicular and&#xD;
             trifascicular block),&#xD;
&#xD;
          6. Myocardial infarction (acute or past), or abnormal Q-waves&#xD;
&#xD;
          7. Symptomatic coronary artery disease&#xD;
&#xD;
          8. Heart failure with reduced ejection fraction &lt;50%&#xD;
&#xD;
          9. Sinus node dysfunction (including sinus rate &lt; 50 bpm)&#xD;
&#xD;
         10. Patients receiving drugs that can induce torsades de pointes&#xD;
&#xD;
         11. Patients receiving medicinal products with narrow therapeutic index (ie, theophylline,&#xD;
             tizanidine, digoxin, lithium, phenytoin or warfarin)&#xD;
&#xD;
         12. Patients who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nikki Adetoro</last_name>
    <phone>443-447-4534</phone>
    <email>NikkiAdetoro@lupin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Universitaire de La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>Cedex</state>
        <zip>13 75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savine Vicart, MD</last_name>
      <phone>33 (0) 1 42 16 16 91</phone>
      <email>savine.vicart@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Savine Vicart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Tard, MD</last_name>
      <phone>33 (0) 3 20 44 59 62</phone>
      <email>CELINE.TARD@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Celine Tard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum</name>
      <address>
        <city>Bochum</city>
        <state>North-Rhine Westphalia</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane Schneider-Gold, MD</last_name>
      <phone>+492345096439</phone>
      <email>Christiane.Schneider-Gold@ruhr-uni-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Christiane Schneider-Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Rosenbohm, MD</last_name>
      <phone>0049 (0)731 177 5261</phone>
      <email>angela.rosenbohm@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Angela Rosenbohm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Hanna, MD</last_name>
      <email>m.hanna@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saam Sedehizadeh, MD</last_name>
      <phone>0115 924 9924</phone>
      <email>Saam.Sedehizadeh@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Saam Sedehizadeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
    <mesh_term>Myotonic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mexiletine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

